8-K
filed June 11, 2026, 4:15 PM ET
ticker CRDF
CIK 0001213037
other
confidence high
sentiment neutral
materiality 0.15
All four proposals approved at Cardiff Oncology 2026 annual meeting, including equity plan increase to 15.15M shares
Cardiff Oncology, Inc.
- All six director nominees elected; broker non-votes of ~22.3M shares for each.
- Ratification of BDO USA as independent auditor for FY2026: 40.24M for, 1.07M against.
- Amendment to 2021 Equity Incentive Plan increasing authorized shares to 15.15M approved: 10.74M for, 8.06M against.
- Advisory say-on-pay vote on named executive officer compensation approved: 17.12M for, 1.77M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cardiff Oncology, Inc. shareholders approved Election of six nominees for director at the 2026-06-11 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 1 . All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the six (6) directors was as follows: Directors For Against Abstain Broker Non Vote Dr. James O. Armitage 18,806,657 0 522,756 22,285,435 Dr. Rodney Markin 18,647,050 0 682,361 22,285,437 Mani Mohindru, Ph.D. 18,942,979 0 386,435 22,285,434 Gary W. Pace, Ph.D. 18,877,743 0 451,668 22,285,437 Renee P. Tannenbaum, Pharm.D. 18,790,068 0 539,345 22,285,435 Lâle White 18,710,040 0 619,373 22,285,435
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cardiff Oncology, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-11 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 4. The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 17,120,176 1,772,185 437,049 22,285,438
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cardiff Oncology, Inc. shareholders approved Amendment to 2021 Equity Incentive Plan to increase number of shares issuable to 15,150,000 shares at the 2026-06-11 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 10,740,460 8,063,520 525,431 22,285,437
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cardiff Oncology, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year 2026 at the 2026-06-11 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 2. The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 40,239,508 1,070,807 304,529 4
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.